Discover your next big idea for life sciences at PACK EXPO Las Vegas
Experience a breakthrough in life sciences packaging—explore solutions from 2,300 suppliers spanning all industries, all in one place this September

Federal judge approves consent decree with New York dietary supplement maker

Mira Health Products manufactured and distributed unapproved and adulterated products

This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.

A federal judge in New York has signed a consent decree for permanent injunction between the United States and Mira Health Products Ltd., a dietary supplement manufacturer located in Farmingdale, New York, and Michael S. Ragno and Michael S. Ragno, Jr.

On July 26, 2013, the FDA issued a warning to consumers not to use or purchase Healthy Life Chemistry By Purity First B-50, a dietary supplement manufactured by Mira. The FDA issued this warning after receiving numerous reports of illness associated with use of the product. An FDA laboratory analysis found that the product contained two drugs that are potentially harmful anabolic steroids—methasterone, a controlled substance, and dimethazine. These ingredients were not listed on the label and should not have been in a dietary supplement because they are illegal drugs and not dietary ingredients.

In August 2013, Mira recalled all dietary supplements manufactured between June 1, 2010 and May 31, 2013.

Mira’s representatives have informed the court that they are out of business and are no longer manufacturing, processing, packing, labeling, holding, or distributing any dietary supplement, any product labeled as such, or any drug.

Under the terms of the consent decree, before Mira can resume operations, the company must first notify the FDA of its intentions at least 60 business days in advance of resuming operations and must retain an independent expert to inspect its operations and certify to the FDA that the necessary corrections have been made.

The company will not be able to resume operations until it receives written notice from the FDA that its operations are compliant with the Federal Food, Drug, and Cosmetic Act and all applicable regulations. Pursuant to the consent decree, the company must, among other things, bring its procedures for manufacturing, packaging and labeling dietary supplements into compliance with federal regulations prior to resuming operations. The company must also recall and destroy, under the FDA’s supervision, all unexpired drugs and dietary supplements manufactured since Aug. 1, 2010.

“By law, dietary supplements must be manufactured according to FDA regulations,” said Melinda K. Plaisier, the FDA’s associate commissioner for regulatory affairs. “This consent decree will ensure that this company cannot harm consumers by selling dietary supplements that do not comply with federal manufacturing requirements.”

United States District Court Judge Joseph F. Bianco of the Eastern District of New York entered the consent decree for permanent injunction against Mira Health Products Ltd on July 1, 2014.

Any illnesses or adverse events related to use of these products should be reported to the FDA at https://www.accessdata.fda.gov/scripts/medwatch/ or by calling 800-322-1088

Pharmaceutical Innovations Report
Discover the latest breakthrough packaging technologies shaping the pharmaceutical sector. This report dives into cutting-edge innovations, from smart containers that enhance patient safety to eco-friendly materials poised to transform the industry’s sustainability practices. All from PACK EXPO. Learn how forward-thinking strategies are driving efficiency and redefining what’s possible in pharma packaging.
Learn More
Pharmaceutical Innovations Report
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
FDA warning letters surge - is your team prepared?